Eribulin Mesylate Injection
Product Images NDC 39822-2080

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 39822-2080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xgen Pharmaceuticals Djb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Taiwan-vial-1mg_2ml (Taiwan Vial 1mg 2ml)

This text describes a single-dose vial of Eribulin Mesylate Injection, containing 0.5 mg/mL for intravenous use as a cytotoxic agent. The medication should be stored at 20° to 25°C, with excursions permitted to 15° to 30°C. It should not be frozen or refrigerated. Additional information on dosage and use can be found in the accompanying prescribing information. The product is manufactured for XGen Pharmaceuticals DB, Inc. in Big Flats, NY, and made by Formosa Laboratories, Inc. in Taiwan. The label includes fields for Lot and Expiration date.*

FDA Label Image

Taiwan-single-carton-1mg_2ml (Taiwan Single Carton 1mg 2ml)

This text contains information about Eribulin Mesylate Injection, which is a cytotoxic agent in a sterile solution for intravenous use. Each single-dose vial contains 1 mg of Eribulin Mesylate in 2 mL of solution, with each mL containing 0.5 mg of the active ingredient. The solution also contains dehydrated alcohol and water for injection. The recommended storage temperature is 20°C to 25°C, with excursions permitted to 15°C to 30°C. It also mentions precautions about not freezing or refrigerating the medication. Additionally, it provides the NDC code and manufacturer information.*

FDA Label Image

Figure 1 (Eribulin Fig1)

This text shows a survival curve comparison between Eribulin Mesylate Injection group (N=508) and the control group (N=258) over 36 months. It indicates the proportion of patients alive at different time points and the number of patients at risk. The survival data is presented on a timeline with specific time intervals.*

FDA Label Image

Figure 2 (Eribulin Fig2)

FDA Label Image

Structural Formula (Eribulin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.